Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: an updated meta-analysis shows oral anticoagulant monotherapy lowers bleeding without raising ischemic events in chronic coronary disease requiring long-term anticoagulation. A population-based study across three decades highlights a rising atrial fibrillation burden with hypertension as the leading contributor, especially in women. A large prospective cohort demonstrates that genetic susceptibility to atrial fibrillation is sex- and clinical r
Summary
Three impactful cardiology studies stand out today: an updated meta-analysis shows oral anticoagulant monotherapy lowers bleeding without raising ischemic events in chronic coronary disease requiring long-term anticoagulation. A population-based study across three decades highlights a rising atrial fibrillation burden with hypertension as the leading contributor, especially in women. A large prospective cohort demonstrates that genetic susceptibility to atrial fibrillation is sex- and clinical risk–dependent, informing precision prevention.
Research Themes
- Optimizing antithrombotic strategies to minimize bleeding without sacrificing ischemic protection
- Sex- and risk-specific prevention of atrial fibrillation integrating genetics and clinical scores
- Epidemiologic trends identifying hypertension as a key, modifiable driver of AF burden
Selected Articles
1. Oral anticoagulant monotherapy in patients with chronic coronary disease: An updated meta-analysis.
Across five RCTs (n=4,964), oral anticoagulant (OAC) monotherapy lowered the composite of cardiovascular death, stroke, myocardial infarction, and major bleeding versus OAC plus single antiplatelet therapy, driven by substantial reductions in bleeding. Ischemic outcomes were comparable between groups, supporting simplified antithrombotic regimens in patients needing long-term anticoagulation.
Impact: Synthesizing randomized evidence, this analysis provides high-level support for OAC monotherapy, balancing efficacy and safety in a common and high-risk population.
Clinical Implications: For chronic coronary disease patients requiring long-term anticoagulation (e.g., atrial fibrillation with stable CAD), consider OAC monotherapy to minimize bleeding risk after the early post-PCI period, absent other indications for antiplatelet therapy. Shared decision-making should account for stent timing, ischemic risk, and bleeding risk.
Key Findings
- OAC monotherapy reduced the primary composite of cardiovascular death, stroke, myocardial infarction, and major bleeding (RR 0.68, 95% CI 0.53-0.85).
- Major bleeding was significantly lower with OAC monotherapy (RR 0.49, 95% CI 0.31-0.77).
- Ischemic outcomes (all-cause death, cardiovascular death, myocardial infarction, stroke, systemic embolism) were comparable between strategies.
- Major or clinically relevant non-major bleeding was reduced with OAC monotherapy (RR 0.51, 95% CI 0.38-0.68).
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials enhances internal validity.
- Consistent findings across multiple efficacy and safety endpoints with risk estimates and confidence intervals.
Limitations
- Only five RCTs with potential heterogeneity in populations, antiplatelet regimens, and follow-up.
- Generalizability may be limited in early post-PCI periods or high ischemic-risk subsets not well represented.
Future Directions: Head-to-head pragmatic trials and IPD meta-analyses stratifying by stent age, bleeding risk, DOAC vs VKA, and presence of complex CAD could refine patient selection and timing for de-escalation.
BACKGROUND: The optimal antithrombotic strategy for patients with chronic coronary disease requiring long-term anticoagulation remains uncertain. While dual therapy with oral anticoagulants (OACs) and antiplatelet agents is common, it significantly increases bleeding risk. This meta-analysis was conducted to compare the efficacy and safety of OAC monotherapy against combination therapy. METHODS: We searched PubMed, Embase, ClinicalTrials.gov, and Cochrane library through August 2025 to identify randomized controlled trials (RCTs) comparing OAC monotherapy to dual therapy (OAC plus a single antiplatelet agent) in patients with chronic coronary disease. The primary outcome was a composite of cardiovascular death, stroke, myocardial infarction, and major bleeding. RESULTS: Five RCTs with 4964 participants were included. OAC monotherapy was associated with a significantly lower risk of the primary composite outcome (RR: 0.68, 95% CI: 0.53-0.85). The risks of all-cause death, cardiovascular death, myocardial infarction, stroke, and systemic embolism were comparable between the two groups. OAC monotherapy significantly reduced the risk of major bleeding (RR: 0.49, 95% CI: 0.31-0.77) and major or clinically relevant non-major bleeding (RR: 0.51, 95% CI: 0.38-0.68). CONCLUSIONS: In patients with chronic coronary disease requiring long-term anticoagulation, OAC monotherapy reduces bleeding complications without increasing the risk of ischemic events compared to dual therapy. These findings support the use of a simplified antithrombotic strategy without antiplatelet therapy in this patient population.
2. Trends in burden of atrial fibrillation over three decades: a population-based study.
In the Rotterdam Study (n=22,546; three epochs, 5-year follow-up each), age- and sex-adjusted AF incidence rose to 52.0 per 1000 person-years in the 2010s, with consistently higher rates in men. Hypertension contributed the largest population attributable fraction to incident AF across all epochs, particularly among women (PAF up to 59.9%), underscoring sex-specific prevention priorities.
Impact: This long-running population-based analysis quantifies AF incidence trends and risk factor contributions, identifying hypertension—especially among women—as the dominant, modifiable driver.
Clinical Implications: Prioritize aggressive, sex-sensitive hypertension control to prevent incident AF, and consider tailored screening and management strategies for women with elevated blood pressure.
Key Findings
- AF incidence rates (per 1000 person-years) across epochs were 36.1 (1990s), 27.4 (2000s), and 52.0 (2010s).
- Men exhibited higher AF incidence than women in each epoch (e.g., 65.6 vs 44.1 in the 2010s).
- Hypertension had the largest PAF for AF across all epochs, with particularly high PAFs among women (up to 59.9% in the 2010s).
- Findings support sex-specific prevention and management strategies centered on blood pressure control.
Methodological Strengths
- Large, population-based cohorts spanning three decades with standardized follow-up.
- Sex-stratified analyses with Cox regression and PAF estimates provide actionable population insights.
Limitations
- Potential changes in AF detection over time and residual confounding despite adjustments.
- Follow-up limited to 5 years per epoch; results from a single European region may limit generalizability.
Future Directions: Evaluate lifetime risk modeling and intervention studies targeting hypertension (especially in women), and validate findings across diverse ancestries and health systems.
BACKGROUND: Atrial fibrillation (AF) is a common sustained cardiac arrhythmia with increasing prevalence and incidence worldwide. However, long-term trends in AF prevalence, incidence, associated risk factors, and the role of comorbidities, including sex-specific differences is limited. METHODS: We included 7750, 7675, and 7121 participants from the population-based Rotterdam Study across three epochs over 3 decades (epoch 1990s: 1989-1993; epoch 2000s: 1997-2001; and epoch 2010s: 2009-2014). We examined trends in incidence rates and estimated incidence rate ratios (IRRs) over time, both overall and stratified by sex. Cox regression were applied to evaluate associations between comorbidities and incident AF to derive HRs with 95% CIs. Population attributable fractions (PAFs) were calculated to quantify the contribution of key comorbidities to AF incidence. RESULTS: The mean (SD) of age in three epochs was around 70 years (epoch 1990s: 70.3 (9.6), epoch 2000s: 70.0 (8.7) and epoch 2010s: 70.4 (9.8)). The follow-up for each participant was 5 years. The age and sex-adjusted AF incidence rates in three epochs were 36.1, 27.4 and 52.0 per 1000 person-years. The AF incidence rates were 31.4, 22.9 and 44.1 for women and 45.0, 34.7 and 65.6 for men, respectively. Hypertension was the most important contributor to incident AF in all three epochs (PAFs were epoch 1990s: 36.0% (95% CI 24.3% to 54.2%), epoch 2000s: 35.0% (95% CI 14.0% to 59.5%) and epoch 2010s: 42.7% (95% CI 22.6% to 61.0%)), especially in women (epoch 1990s: 46.6% (95% CI 24.0% to 68.3%), epoch 2000s: 38.60% (95% CI 11.9% to 68.9%) and epoch 2010s: 59.9% (95% CI 40.5% to 82.5%)). CONCLUSION: The increasing burden of AF over the last three decades for both women and men calls for improved sex-specific AF prevention and management strategies. Hypertension remains to be a principal contributor to the population burden of AF, in particular among women. Effective sex-specific management of hypertension is a promising target in AF prevention strategies.
3. Sex Differences in the Association Between Polygenic Risk Score and Atrial Fibrillation Incidence: A Prospective Cohort Study.
Among 444,463 UK Biobank participants followed for ~15 years, 31,070 developed AF. The AF polygenic risk score showed sex-specific effects modified by clinical risk: women had higher genetic susceptibility at higher CHARGE-AF risk, whereas men had higher susceptibility at lower CHARGE-AF. Significant multiplicative and tripartite interactions support integrating sex and clinical risk when interpreting PRS.
Impact: This very large cohort demonstrates that genetic risk for AF is context-dependent by sex and clinical burden, advancing precision prevention and risk communication.
Clinical Implications: When considering PRS for AF, interpret results through the lens of sex and clinical risk (e.g., CHARGE-AF). High-risk women may merit intensified prevention and monitoring; low clinical risk men with high PRS may also warrant earlier surveillance.
Key Findings
- Over 14.67 ± 3.01 years, 31,070 incident AF cases occurred among 444,463 participants.
- Significant interaction between male sex and higher AF-PRS (interaction HR 0.95, 95% CI 0.91-1.00; P=0.031).
- Women exhibited greater genetic susceptibility at higher CHARGE-AF (HR 1.99 vs 1.83 in men), while men did so at lower CHARGE-AF (HR 2.33 vs 2.11 in women).
- A significant tripartite interaction (AF-PRS × sex × CHARGE-AF, HR 0.84; P<0.001) confirmed the sex- and risk-dependent effects.
Methodological Strengths
- Very large sample size with long follow-up and comprehensive covariate adjustment.
- Formal tests of multiplicative and three-way interactions stratified by clinical risk burden.
Limitations
- UK Biobank selection bias may limit generalizability; AF ascertainment via ICD-10 may miss subclinical cases.
- PRS thresholds and ancestry composition may limit transferability; clinical utility not tested in an interventional framework.
Future Directions: External validation across ancestries, prospective utility trials integrating PRS with sex- and risk-stratified prevention, and cost-effectiveness analyses are needed.
BACKGROUND: Although sex disparities in atrial fibrillation (AF) epidemiology and outcomes are well documented, the role of sex in modulating genetic susceptibility to incident AF remains poorly characterized. In this study we assessed sex-specific effects of polygenic risk score (PRS) on AF incidence and the sex-specific PRS effects, stratified by the Cohorts for Heart and Aging Research in Genomic Epidemiology for Atrial Fibrillation (CHARGE-AF) clinical risk score. METHODS: This prospective cohort study included 444,463 AF-free UK Biobank participants (54.67% women; mean age 56.46 ± 8.09 years). Participants were stratified by sex, AF-PRS (cutoff ≥ 0.295), and CHARGE-AF clinical risk score (cutoff ≥ 12.048). Incident AF was ascertained via ICD-10 codes. Cox hazards regression (adjusting for clinical, metabolic, lifestyle, and socioeconomic covariables) was used to evaluate the multiplicative interactions among AF-PRS, sex, and CHARGE-AF. RESULTS: Over 14.67 ± 3.01 years, 31,070 participants experienced incident AF. A significant interaction between male sex and higher AF-PRS emerged (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.91-1.00; P = 0.031). Women were more genetically susceptible to AF at higher CHARGE-AF (HR 1.99 vs 1.83 in men) and men at lower CHARGE-AF (HR 2.33 vs 2.11 in women). In addition, the tripartite interaction (AF-PRS × sex × CHARGE-AF, HR 0.84; P < 0.001) further validated the sex-specific results stratified by CHARGE-AF. CONCLUSIONS: The association between AF-PRS and incident AF is modified by sex, with clinical risk burden modifying sex-related PRS effects. Women presented with higher genetic susceptibility at higher CHARGE-AF, and men at lower CHARGE-AF. Rethinking AF genetic susceptibility in a sex- and context-dependent manner may enhance precise prevention.